BlackRock Inc. acquired a new stake in Cabaletta Bio, Inc. during the second quarter. The asset manager purchased 10,754,701 shares. A September 2, 2026, SEC filing disclosed the transaction. The position is valued at approximately $33.45 million.
This investment represents a 6.6% ownership stake in the autoimmune-focused cell therapy company. Analysts maintain a consensus Moderate Buy rating on the stock. The average price target for Cabaletta Bio is $15.33.